ctDNA在转移性去势抵抗性前列腺癌诊断中的应用现状

Application of ctDNA in the diagnosis of metastatic castration-resistant prostate cancer

转移性去势抵抗性前列腺癌(metastatic castration-resistant prostate cancer,mCRPC)是不可治愈的,严重威胁着男性患者的 健康,也是人类恶性肿瘤治疗的一个重要难题。循环肿瘤DNA( circulating tumor DNA,ctDNA)是 一种非侵入性、可重复的评估肿 瘤基因组的工具,具有全面了解恶性肿瘤的潜力,在mCRPC中也进行了深入研究。本文将对ctDNA在mCRPC中的检测情况,以 及用于mCRPC患者监测及对耐药性机制等相关研究现状进行综述,并提出对未来可能有参考价值的研究方向。

Metastatic castration-resistant prostate cancer(mCRPC)is an important problem faced by mankind and is an incurable disease that threatens the survival of men with this disease.Circulating tumor DNA(ctDNA)can be used as a noninvasive and repeatable tool for evaluating tumor genomes.It has the potential to fully improve our understanding of malignant tumors,and is increasingly being used to study mCRPC.In this paper,we reviewed the status of employment of ctDNA for detecting and monitoring mCRPC,as well as its application in investigating the mechanism of drug resistance and other relevant research.We also propose future research direction that could serve as a reference.